Section 232 pharmaceutical tariffs enter final phase; mitigation window open
The final phase of Section 232 pharmaceutical tariffs under Proclamation 11020 took effect September 29, 2026, exposing many imported patented drugs and ingredients to duties that counsel say remain addressable.
Per a Wilmer Cutler alert, the final phase of the Section 232 pharmaceutical tariffs established by Presidential Proclamation 11020 became effective on September 29, 2026, subjecting many imported patented pharmaceuticals and associated ingredients to duties. The alert's focus is practical: firms and their counsel still have room to consider duty-mitigation strategies rather than treating the tariffs as a fixed, unavoidable cost.
Why sophisticated counsel should care: Section 232 duties on finished pharmaceuticals and on associated ingredients reshape landed-cost calculations, supply-contract terms and inventory planning for drug and biotech clients, and they interact with existing foreign-trade-zone, bonded-warehouse and tariff-exclusion options. Because the tariff architecture is proclamation-driven, scope, product coverage and phase-in mechanics can change through successive proclamations and implementing actions, so today's supply chain can differ materially from an earlier model.
Concrete next step: clients with cross-border pharmaceutical flows should refresh customs classifications and origin analyses, quantify duty exposure at the ingredient and finished-product levels, evaluate mitigation mechanisms with customs counsel, and track further implementing guidance. The alert excerpt does not specify rates, exclusions or procedural deadlines, which should be confirmed against the Proclamation text and CBP instructions.